5:27 PM
 | 
Jan 04, 2010
 |  BC Extra  |  Company News

Adventrx submits ANX-530 NDA, raises $19M

Adventrx Pharmaceuticals Inc. (NYSE-A:ANX) submitted an NDA to FDA for ANX-530 to treat non-small cell lung cancer (NSCLC). The NDA was submitted under section 505(b)(2) of...

Read the full 117 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >